NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Ardelyx, Inc. (ARDX) Stock Analysis

Ardelyx, Inc. (ARDX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ARDX

$3.13

−$0.08 (−2.49%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARDX with… →

ARDX Key Statistics

As of Oct 21, 2026
Trading
Open
$3.23
Previous Close
$3.21
Day's Range
3.12–3.23
52-Week Range
3.05–8.40
Volume
3.02M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.68
Valuation
Market Cap
$808.13M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.78
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.79
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.23
Financials (FY)
Revenue (FY)
$407.32M+22.09%
Net Income (FY)
−$61.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
−12.35%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
258.19M
1-Year Return
−40.83%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
4.37M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ARDX closed at $3.13, −40.83% over 1 year.

Ardelyx, Inc. (ARDX) has a market capitalization of $808.13M.

In fiscal 2025, ARDX reported revenue of $407.32M.

ARDX Stock Return by Calendar Year

Ardelyx, Inc. (ARDX) 10-year return: what $10,000 became

1 year
$10,000 $5,917
−40.83%
5 years
$10,000 $26,303
+163.03%
10 years
$10,000 $2,371
−76.29%

If you had invested $10,000 in Ardelyx, Inc. (ARDX) 10 years ago, at the close on October 21, 2016, it would have been worth $2,371 at the close on October 21, 2026: −76.29% in total, −13.40% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−46.31%
2025+14.99%
2024−18.23%
2023+117.54%
2022+159.09%
2021−83.00%
2020−13.79%
2019+319.27%
2018−72.88%
2017−53.52%
2016 (partial year)+38.00%

As of October 21, 2026.

ARDX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$407.32M−$61.60M−15.1%
2024$333.62M−$39.14M−11.7%
2023$124.46M−$66.07M−53.1%
2022$52.16M−$67.21M−128.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$407.32M$367.78M−$40.98M−$61.60M−15.1%
2024$333.62M$283.06M−$27.95M−$39.14M−11.7%
2023$124.46M$106.66M−$63.28M−$66.07M−53.1%
2022$52.16M$48.04M−$63.76M−$67.21M−128.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ARDX Valuation vs Biotechnology Median

Median of 608 stocks
MetricARDXBiotechnology medianvs median
P/S ratio1.7913.300.1x the median
Profit margin−12.35%−38.31%26.0 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Ardelyx, Inc. (ARDX) at $808.13M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 489 employees.

Over the past 52 weeks the price has ranged from $3.05 to $8.40. ARDX last closed at $3.13 on October 21, 2026. That is −$0.08 (−2.49%) against the previous close. The latest close sits 2.62% above that 52-week low.

Financial Health

In fiscal 2025, Ardelyx, Inc. reported revenue of $407.32M. Against the prior fiscal year total of $333.62M, that is a change of +22.09%. The same year closed with a net loss of $61.60M. Profit margin runs at −12.35%. That is 26 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.23.

Across the 4 fiscal years on file, revenue moves from $52.16M in 2022 to $407.32M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 10.78. The price-to-sales ratio is 1.79. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 0.68. Annualized volatility over the trailing 10 years is 83.83%. Over the trailing twelve months the total return is −40.83%. Measured over 10 years, that is −13.40% a year compounded.

Growth & Income

No dividend is on file for ARDX.

Across the complete calendar years on file, 2019 returned +319.27% and 2021 returned −83.00%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the total return is −46.31%.

Peer Comparison

Ardelyx, Inc. (ARDX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ardelyx, Inc. ARDX $808.13M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Ardelyx, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Ardelyx, Inc.

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Visit website →